{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:55:19Z","timestamp":1789732519245,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejps.2025.107422","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T15:36:16Z","timestamp":1766331376000},"page":"107422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["VA1213, a selective COX-2 inhibitor, exhibits antitumor activity by suppressing EGFR, AKT, and ERK1\/2 phosphorylation"],"prefix":"10.1016","volume":"219","author":[{"given":"Valerio","family":"Ciccone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cecchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Frosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Saletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Maramai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Anzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Donnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Morbidelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejps.2025.107422_bib0001","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1021\/jm301370e","article-title":"Novel analgesic\/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as cyclooxygenase-2 inhibiting nitric oxide donors","volume":"56","author":"Anzini","year":"2013","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejps.2025.107422_bib0002","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1021\/jm800084s","article-title":"Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity","volume":"51","author":"Anzini","year":"2008","journal-title":"J. Med. Chem."},{"issue":"31","key":"10.1016\/j.ejps.2025.107422_bib0003","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.1074\/jbc.M201119200","article-title":"Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line","volume":"277","author":"Arico","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2025.107422_bib0004","series-title":"Vicinal Diaryl Substituted Heterocycles [Internet]","first-page":"1","article-title":"Chapter 1 - vicinal diaryl heterocyclic system: a privileged scaffold in the discovery of potential therapeutic agents","author":"Barmade","year":"2018"},{"issue":"19","key":"10.1016\/j.ejps.2025.107422_bib0005","doi-asserted-by":"crossref","first-page":"31270","DOI":"10.18632\/oncotarget.16116","article-title":"PGE2\/EP3\/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells","volume":"8","author":"Bazzani","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ejps.2025.107422_bib0006","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1021\/jm049121q","article-title":"1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors","volume":"48","author":"Biava","year":"2005","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejps.2025.107422_bib0007","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1021\/jm200715n","article-title":"Novel analgesic\/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties","volume":"54","author":"Biava","year":"2011","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejps.2025.107422_bib0008","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.2005.09.051","article-title":"COX-2: a molecular target for colorectal cancer prevention","volume":"23","author":"Brown","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"70","key":"10.1016\/j.ejps.2025.107422_bib0009","doi-asserted-by":"crossref","first-page":"115526","DOI":"10.18632\/oncotarget.23308","article-title":"Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2025.107422_bib0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.intimp.2018.08.025","article-title":"In vitro comprehensive analysis of VA692 a new chemical entity for the treatment of osteoarthritis","volume":"64","author":"Cheleschi","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"17","key":"10.1016\/j.ejps.2025.107422_bib0011","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.3390\/cancers14174240","article-title":"The nitric oxide donor [Zn(PipNONO)Cl] exhibits antitumor activity through inhibition of epithelial and endothelial mesenchymal transitions","volume":"14","author":"Ciccone","year":"2022","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.ejps.2025.107422_bib0012","doi-asserted-by":"crossref","first-page":"13353","DOI":"10.18632\/oncotarget.24350","article-title":"The metal-nonoate Ni(SalPipNONO) inhibits in vitro tumor growth, invasiveness and angiogenesis","volume":"9","author":"Ciccone","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2025.107422_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116252","article-title":"ALDH1A1 confers resistance to RAF\/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K\/AKT signaling","volume":"224","author":"Ciccone","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107422_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijmm.2022.5155","article-title":"ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL\u20118\/Notch signaling cascade","volume":"50","author":"Ciccone","year":"2022","journal-title":"Int. J. Mol. Med."},{"issue":"10","key":"10.1016\/j.ejps.2025.107422_bib0015","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1503\/cmaj.050456","article-title":"New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra)","volume":"172","author":"Cotter","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.ejps.2025.107422_bib0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejmech.2015.12.044","article-title":"Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity","volume":"109","author":"Di Capua","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejps.2025.107422_bib0017","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1096\/fj.06-7581com","article-title":"EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1\/2 pathways","volume":"21","author":"Donnini","year":"2007","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.ejps.2025.107422_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2024.119810","article-title":"ERK5 mediates pro-tumorigenic phenotype in non-small lung cancer cells induced by PGE2","volume":"1871","author":"Filippelli","year":"2024","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Cell Res."},{"issue":"12","key":"10.1016\/j.ejps.2025.107422_bib0019","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/biology9120434","article-title":"Prostaglandin E2 and cancer: insight into tumor progression and immunity","volume":"9","author":"Finetti","year":"2020","journal-title":"Biology"},{"issue":"8","key":"10.1016\/j.ejps.2025.107422_bib0020","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/molecules30081733","article-title":"Rosmarinus officinalis L. as fascinating source of potential anticancer agents targeting aromatase and COX-2: an overview","volume":"30","author":"Gargano","year":"2025","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ejps.2025.107422_bib0021","first-page":"471","article-title":"Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer","volume":"15","author":"Gee","year":"2006","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0022","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/molpharm.120.000210","article-title":"Identification of Celecoxib-targeted proteins using label-free thermal proteome profiling on rat hippocampus","volume":"99","author":"Gholizadeh","year":"2021","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2025.107422_bib0023","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1734-1140(10)70262-0","article-title":"COX-2 as a target for cancer chemotherapy","volume":"62","author":"Ghosh","year":"2010","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.ejps.2025.107422_bib0024","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genom."},{"issue":"3","key":"10.1016\/j.ejps.2025.107422_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.ejps.2025.107422_bib0026","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.3892\/mmr.2015.3804","article-title":"Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase\/Akt\/mechanistic target of rapamycin pathways","volume":"12","author":"Han","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0027","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107422_bib0028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/aps.2013.125","article-title":"Yhhu3813 is a novel selective inhibitor of c-met Kinase that inhibits c-met-dependent neoplastic phenotypes of human cancer cells","volume":"35","author":"He","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.ejps.2025.107422_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13578-019-0361-4","article-title":"Signaling pathways involved in colorectal cancer progression","volume":"9","author":"Koveitypour","year":"2019","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejps.2025.107422_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110389","article-title":"Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: recent advancement","volume":"129","author":"Li","year":"2020","journal-title":"Biomed. Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.ejps.2025.107422_bib0032","first-page":"165","article-title":"The role of cyclooxygenase-2 in colorectal carcinogenesis","volume":"16","author":"Liu","year":"2017","journal-title":"Clin. Colorectal. Cancer"},{"key":"10.1016\/j.ejps.2025.107422_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.09.008","volume":"78","author":"Martelli","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"21","key":"10.1016\/j.ejps.2025.107422_bib0034","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15481","article-title":"Celecoxib impairs primary human myoblast proliferation and differentiation independent of cyclooxygenase 2 inhibition","volume":"10","author":"Matheny","year":"2022","journal-title":"Physiol. Rep."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0035","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1158\/1078-0432.CCR-09-0788","article-title":"Cyclooxygenase-2 and cancer treatment: understanding the risk should Be worth the reward","volume":"16","author":"Menter","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0036","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3892\/mco.2014.327","article-title":"Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients","volume":"2","author":"Mosalpuria","year":"2014","journal-title":"Mol. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejps.2025.107422_bib0037","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin. Immunopathol."},{"issue":"3","key":"10.1016\/j.ejps.2025.107422_bib0038","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nm0302-289","article-title":"Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy","volume":"8","author":"Pai","year":"2002","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ejps.2025.107422_bib0039","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.clim.2006.01.016","article-title":"Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases","volume":"119","author":"Park","year":"2006","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0040","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-04-1877","article-title":"Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism","volume":"11","author":"Patel","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0041","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ebiom.2015.04.013","article-title":"COX-2 and EGFR: partners in crime split by Aspirin","volume":"2","author":"Patrignani","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejps.2025.107422_bib0042","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bcp.2018.05.013","article-title":"Celecoxib inhibits mitochondrial O2 consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway","volume":"154","author":"Pritchard","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107422_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.637504","article-title":"Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer","volume":"11","author":"Pu","year":"2021","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.ejps.2025.107422_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115045","article-title":"Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylpyrrol-3-substituted scaffold","volume":"27","author":"Reale","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejps.2025.107422_bib0045","doi-asserted-by":"crossref","first-page":"e1596","DOI":"10.1002\/wsbm.1596","article-title":"Cyclooxygenase-2 as a therapeutic target against human breast cancer: a comprehensive review","volume":"15","author":"Sahu","year":"2023","journal-title":"WIREs Mech. Dis."},{"key":"10.1016\/j.ejps.2025.107422_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114615","article-title":"Novel analgesic\/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyethyl sulfides and related compounds as cyclooxygenase-2 inhibitors containing a nitric oxide donor moiety endowed with vasorelaxant properties","volume":"241","author":"Saletti","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejps.2025.107422_bib0047","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/138955707780859431","article-title":"Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy","volume":"7","author":"Sarkar","year":"2007","journal-title":"Mini. Rev. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejps.2025.107422_bib0048","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jama.282.13.1254","article-title":"The relationship between cyclooxygenase-2 expression and colorectal cancer","volume":"282","author":"Sheehan","year":"1999","journal-title":"JAMa"},{"issue":"4","key":"10.1016\/j.ejps.2025.107422_bib0049","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.ejps.2025.107422_bib0050","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/030079907X210561","article-title":"Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization","volume":"23","author":"Sun","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"10.1016\/j.ejps.2025.107422_bib0051","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1073\/pnas.94.7.3336","article-title":"Cyclooxygenase-2 expression in human colon cancer cells increases metastatic\u2009potential","volume":"94","author":"Tsujii","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"20","key":"10.1016\/j.ejps.2025.107422_bib0052","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.3390\/molecules24203722","article-title":"Nitric oxide donor DETA\/NO inhibits the growth of endometrial cancer cells by upregulating the expression of RASSF1 and CDKN1A","volume":"24","author":"Waheed","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejps.2025.107422_bib0053","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13046-019-1361-2","article-title":"Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejps.2025.107422_bib0054","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1172\/JCI97953","article-title":"Role of prostanoids in gastrointestinal cancer","volume":"128","author":"Wang","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ejps.2025.107422_bib0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00001813-200202000-00003","article-title":"COX-2 inhibitors in cancer treatment and prevention, a recent development","volume":"13","author":"Xu","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"9","key":"10.1016\/j.ejps.2025.107422_bib0056","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.3390\/curroncol29090482","article-title":"The efficacy and safety of Celecoxib in addition to standard cancer therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Ye","year":"2022","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.ejps.2025.107422_bib0057","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3390\/ijms21072605","article-title":"Anti-inflammatory drugs as anticancer agents","volume":"21","author":"Zappavigna","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ejps.2025.107422_bib0058","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.3390\/ijms22073622","article-title":"High ROS production by Celecoxib and enhanced sensitivity for death ligand-induced apoptosis in cutaneous SCC cell lines","volume":"22","author":"Zhu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2025.107422_bib0059","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3892\/etm.2017.4287","article-title":"Autophagy activated by the c\u2011Jun N\u2011terminal kinase\u2011mediated pathway protects human prostate cancer PC3 cells from celecoxib\u2011induced apoptosis","volume":"13","author":"Zhu","year":"2017","journal-title":"Exp. Ther. Med."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725004191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725004191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:29:32Z","timestamp":1777591772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725004191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"alternative-id":["S0928098725004191"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107422","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VA1213, a selective COX-2 inhibitor, exhibits antitumor activity by suppressing EGFR, AKT, and ERK1\/2 phosphorylation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107422"}}